Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MyCART
- Development stage
- Preclinical
- Lead developer
- MicroCrispr
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
MyCART is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed by MicroCrispr. It is designed to treat B-cell malignancies, such as B-cell lymphoma and leukemia, by engineering a patient's own T cells to identify and destroy cancerous B cells. The program is currently in the preclinical development phase and utilizes MicroCrispr's proprietary cell engineering platform to create personalized living therapeutics for hematologic cancers. By modifying T cells to express a CAR specific to B-cell antigens, MyCART enables the patient's immune system to recognize and eliminate malignant cells.
Beyond the preview
Go deeper on MyCART.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MyCART.